Medtronic received a 'Buy' rating from TD Cowen, bolstered by favorable CMS coverage terms and the tailwinds of Trump-era tariffs benefiting AI stocks.
2 reports, 1 independent
Updated Sep 2
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Medtronic received a 'Buy' rating from TD Cowen, bolstered by favorable CMS coverage terms and the tailwinds of Trump-era tariffs benefiting AI stocks.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Medtronic plans global launch of Nell-EQ system after receiving FDA 510(k) clearance, while Trump-era tariffs benefit AI stocks.Sub-event
Medtronic benefits from favorable CMS coverage terms and analyst upgrades amid Trump-era policy tailwinds.1 source
Keep exploring
The entities involved
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
-
Medtronic plc
medical device company
-
CMS
International law firm
Coverage
Newest first; wire copies grouped- Insider MonkeyTD Cowen Affirms Buy Rating on Medtronic, Inc. (MDT) on RDN Therapy Prospects Medtronic plc (NYSE:MDT) is one of the top stock picks in Ken Griffin’s portfolio. On August 25, analysts at TD Cowen rei
- Unknown outlet